Kerry Reports €3.3BN H1 Revenue, Emphasises Protein and Bio-Fermented Growth
Kerry Group’s H1 2026 results reveal a €3.3 billion revenue, with significant growth driven by functional ingredients like protein, enzymes, and bio-fermented solutions across health and wellness categories. Supplement brand owners should note the pivot towards proactive health and novel formats.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Dublin, Ireland — 24 July 2026
Kerry Group has announced a group revenue of €3.3 billion for the first half of 2026, alongside an EBITDA of €558 million. The Irish food and nutrition conglomerate highlighted a substantial uptick in customer innovation activities across multiple markets. This trend is particularly pronounced within the health and wellness sector, which is increasingly focused on high-protein formulations, proactive health solutions, and the development of novel product formats.
The group's performance was underpinned by strong demand for its diverse portfolio of taste and biotechnology solutions. Key growth drivers included Tastesense salt and sugar reduction technologies, botanicals, natural extracts, and specialised taste solutions engineered for high-protein applications. Furthermore, the company reported significant growth in its enzyme and bio-fermented ingredient divisions, underscoring a strategic shift towards advanced functional ingredients.
This sustained growth in functional territories by a major supplier like Kerry indicates a strong market pull for ingredients that deliver explicit health benefits. For supplement manufacturers, this translates into increased competition for high-quality protein sources and a greater emphasis on advanced biotechnological inputs. Procurement leads should anticipate potential lead time extensions for such ingredients and assess the need for diversified supplier bases.
What this means for United Kingdom
UK brand owners face a direct impact on ingredient procurement and product development strategies. The heightened demand signal from Kerry suggests potential cost increases of 5-10% for premium protein and bio-fermented ingredients within the next 6-9 months, eroding margins if not managed proactively. Regulatory bodies like the FSA and MHRA are increasingly scrutinising 'proactive health' claims, necessitating robust substantiation for new product launches. Retailers such as Boots and Holland & Barrett are actively seeking differentiated functional products; brand owners that can swiftly reformulate into palatable, novel formats utilising these high-demand ingredients will gain significant competitive advantage and shelf space.
The investment by Kerry into advanced functional ingredients means their enterprise clients are pushing new product development in those areas. This upstream activity will cascade down to smaller brand owners through ingredient availability and pricing. Brands leveraging similar ingredient profiles will need to ensure a compelling value proposition to justify potential higher price points to consumers actively seeking 'proactive health' benefits.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.